Loading viewer...
earnings
Format: PDF earnings
Interim financial report for ALSO-Actebis Group covering H1 2011, presenting stable net sales of EUR 2.86 billion and adjusted EBITDA of EUR 41.9 million. The report outlines integration progress following the merger of ALSO and Actebis, and provides guidance for 2011 EBITDA of EUR 85-95 million with medium-term targets of EUR 120-130 million through the MORE optimization program.
earnings
19 Pages
Five Prime Therapeutics